PE20231561A1 - Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2 - Google Patents

Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2

Info

Publication number
PE20231561A1
PE20231561A1 PE2023001921A PE2023001921A PE20231561A1 PE 20231561 A1 PE20231561 A1 PE 20231561A1 PE 2023001921 A PE2023001921 A PE 2023001921A PE 2023001921 A PE2023001921 A PE 2023001921A PE 20231561 A1 PE20231561 A1 PE 20231561A1
Authority
PE
Peru
Prior art keywords
seq
antibody
claudin
tumors
drug conjugates
Prior art date
Application number
PE2023001921A
Other languages
English (en)
Inventor
Lukas Bammert
Sadilkova Lenka Kyrych
Simona Hoskova
Iva Valentova
Lorenz Waldmeier
Roger Beerli
Ulrich Moebius
Original Assignee
Sotio Biotech A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sotio Biotech A S filed Critical Sotio Biotech A S
Publication of PE20231561A1 publication Critical patent/PE20231561A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
    • A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Se refiere a un conjugado anticuerpo-farmaco que tiene la formula general A-(L-T)n, en donde, a) A es un anticuerpo o fragmento del mismo que se une a CLDN18.2 que comprende las secuencias de las HCDR1, HCDR2 y HCDR3 de las SEQ ID NO: 21, SEQ ID NO: 22 y SEQ ID NO: 23 respectivamente, y las secuencias de las LCDR1, LCDR2 y LCDR3 de la SEQ ID NO: 24, SEQ ID NO: 25 y SEQ ID NO: 26, respectivamente; b) L es un enlazador y c) T es una toxina; donde la toxina es una antraciclina, n es un numero entero entre 1 y 10, o una sal farmaceuticamente aceptable o un ester del mismo.
PE2023001921A 2020-12-23 2021-12-23 Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2 PE20231561A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20216800 2020-12-23
PCT/EP2021/087495 WO2022136642A1 (en) 2020-12-23 2021-12-23 Tumor-specific claudin 18.2 antibody-drug conjugates

Publications (1)

Publication Number Publication Date
PE20231561A1 true PE20231561A1 (es) 2023-10-03

Family

ID=73856974

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023001921A PE20231561A1 (es) 2020-12-23 2021-12-23 Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2

Country Status (13)

Country Link
US (1) US20240100180A1 (es)
EP (1) EP4267194A1 (es)
JP (1) JP2024500242A (es)
KR (1) KR20230124037A (es)
CN (1) CN116635085A (es)
AU (1) AU2021405049A1 (es)
CA (1) CA3199830A1 (es)
CL (1) CL2023001800A1 (es)
IL (1) IL302894A (es)
MX (1) MX2023007644A (es)
PE (1) PE20231561A1 (es)
TW (1) TW202241519A (es)
WO (1) WO2022136642A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022325498A1 (en) 2021-08-13 2024-02-01 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
WO2024050524A1 (en) 2022-09-01 2024-03-07 University Of Georgia Research Foundation, Inc. Compositions and methods for directing apolipoprotein l1 to induce mammalian cell death

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000015659A2 (en) 1998-09-16 2000-03-23 Zymogenetics, Inc. Stomach polypeptide zsig28
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
DE102004024617A1 (de) 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
EP1790664A1 (en) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Monoclonal antibodies against claudin-18 for treatment of cancer
EP1997832A1 (en) 2007-05-29 2008-12-03 Ganymed Pharmaceuticals AG Monoclonal antibodies against Claudin-18 for treatment of cancer
CN102159248B (zh) 2008-07-15 2013-09-11 健泰科生物技术公司 蒽环类衍生物缀合物、它们的制备方法以及它们作为抗肿瘤化合物的用途
WO2013167153A1 (en) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Antibodies useful in cancer diagnosis
WO2013174404A1 (en) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
RU2678127C2 (ru) 2012-11-13 2019-01-23 Бионтех Аг Агенты для лечения экспрессирующих клаудин раковых заболеваний
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AR096687A1 (es) 2013-06-24 2016-01-27 Genentech Inc Anticuerpos anti-fcrh5
CA2971634C (en) 2014-12-23 2024-06-04 Nbe-Therapeutics Ag Binding protein drug conjugates comprising anthracycline derivatives
WO2016165762A1 (en) 2015-04-15 2016-10-20 Ganymed Pharmaceuticals Ag Drug conjugates comprising antibodies against claudin 18.2
SG11201900171QA (en) 2016-07-08 2019-02-27 Carsgen Therapeutics Co Ltd Antibody for anti-claudin 18a2 and use thereof
WO2019173420A1 (en) 2018-03-08 2019-09-12 Phanes Therapeutics, Inc. Anti-claudin 18.2 antibodies and uses thereof
WO2019175617A1 (en) 2018-03-10 2019-09-19 Pratik Sharma Data redundancy and elimination module
JP2021515583A (ja) * 2018-03-14 2021-06-24 ベイジン シュアンイー ファーマサイエンシーズ カンパニー， リミテッド 抗クローディン１８．２抗体
EP3794037A4 (en) 2018-05-18 2022-03-02 Lanova Medicines Limited Company ANTI-CLAUDIN 18.2 ANTIBODIES AND USES THEREOF
JP7468903B2 (ja) 2018-06-17 2024-04-16 エルアンドエル バイオファーマ カンパニー リミテッド Ｃｌｄｎ１８．２を標的とする抗体、二重特異性抗体、ａｄｃ及びｃａｒならびにその使用
WO2020018852A2 (en) 2018-07-18 2020-01-23 Askgene Pharma Inc. Novel antibodies and methods for making and using the same
WO2020023679A1 (en) 2018-07-25 2020-01-30 Accurus Biosciences, Inc. Novel cldn 18.2-specific monoclonal antibodies and methods of use thereof
PE20211400A1 (es) 2018-08-03 2021-07-27 Amgen Res Munich Gmbh Constructos de anticuerpos para cldn18.2 y cd3
WO2020038404A1 (zh) 2018-08-22 2020-02-27 瑞阳(苏州)生物科技有限公司 抗人claudin 18.2单克隆抗体及其应用
CN110862454B (zh) 2018-08-27 2022-12-30 南京圣和药业股份有限公司 一种抗Claudin18_2抗体及其应用
EP3858384A4 (en) 2018-09-30 2022-07-06 CRAGE medical Co., Limited COMBINATION THERAPY OF CLDN18 ANTIBODY AND CHEMOTHERAPEUTICS
KR20210093879A (ko) 2018-10-22 2021-07-28 상하이 젠베이스 바이오테크놀로지 씨오., 엘티디. 항-cldn18.2 항체 및 이의 용도
JP2022516505A (ja) 2018-12-28 2022-02-28 スパークス・セラピューティクス・インコーポレイテッド 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
CN113166246A (zh) 2018-12-28 2021-07-23 四川科伦博泰生物医药股份有限公司 一种抗体及其用途
JP2022515487A (ja) 2018-12-28 2022-02-18 ナンジン、ジェンスクリプト、バイオテック、カンパニー、リミテッド クローディン１８．２結合部分およびその利用
CN109762067B (zh) 2019-01-17 2020-02-28 北京天广实生物技术股份有限公司 结合人Claudin 18.2的抗体及其用途
CN113645996B (zh) 2019-02-01 2024-04-02 新石生物制药有限公司 抗claudin 18抗体及其使用方法
TW202102546A (zh) 2019-04-01 2021-01-16 大陸商江蘇恆瑞醫藥股份有限公司 密蛋白抗體及其應用
JP2023507664A (ja) * 2019-12-23 2023-02-24 ソティオ バイオテック エイ．エス． 腫瘍特異的クローディン１８．２抗体
CN113929780A (zh) 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体

Also Published As

Publication number Publication date
CA3199830A1 (en) 2022-06-30
TW202241519A (zh) 2022-11-01
CN116635085A (zh) 2023-08-22
WO2022136642A1 (en) 2022-06-30
IL302894A (en) 2023-07-01
EP4267194A1 (en) 2023-11-01
MX2023007644A (es) 2023-07-07
CL2023001800A1 (es) 2023-12-11
KR20230124037A (ko) 2023-08-24
JP2024500242A (ja) 2024-01-05
US20240100180A1 (en) 2024-03-28
AU2021405049A1 (en) 2023-06-22

Similar Documents

Publication Publication Date Title
PE20231561A1 (es) Conjugados anticuerpo-farmaco especificos para tumores con claudina 18.2
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
IL277242B1 (en) Antibodies that bind cd39 and uses thereof
AR112768A1 (es) Anticuerpos anti-tigit
JP2016135783A5 (es)
NZ583605A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
AR110017A1 (es) Anticuerpos de pd-1 y usos de estos
PE20181921A1 (es) NUEVOS ANTICUERPOS ANTI-SIRPa Y SUS APLICACIONES TERAPEUTICAS
PE20090161A1 (es) Anticuerpos monoclonales anti cxcl13
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20181090A1 (es) Modulacion y tratamiento inmunes de tumores solidos con anticuerpos que se unen especificamente a cd38
NZ608660A (en) Anti-cd48 antibodies and uses thereof
HRP20160485T1 (hr) Anti-mezotelinska protutijela i njihova uporaba
PE20191408A1 (es) Proteinas de union a antigeno st2
JP2017510559A5 (es)
JP2013121353A5 (es)
NZ714313A (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
RS54111B1 (en) ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
CU24636B1 (es) Anticuerpos que reconocen tau en los residuos 257-271 o 320-334 de la seq id no: 1
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
NZ599777A (en) Antibodies that bind human dendritic and epithelial cell 205 (DEC-205)
AR091701A1 (es) Anticuerpos anti-cd22 e inmunoconjugados
AR123480A1 (es) Moléculas de unión terapéuticas